| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026. |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
(a)Penumbra, Inc. (“Penumbra” or the “Company”) held its Annual Meeting of Stockholders on June 18, 2026 (the “Annual Meeting”). Proxies for the Annual Meeting were solicited pursuant to Regulation 14A of the Securities Exchange Act of 1... |
| 07 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
(a)On May 6, 2026, Penumbra, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). Proxies for the Special Meeting were solicited pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amende... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026. |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., Feb. 25, 2026 /PR Newswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. |
| 15 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Exhibit A – Second Amended and Restated Certificate of Incorporation of the Surviving Corporation |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025. |
| 27 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
ALAMEDA, Calif. – August 27, 2025 – Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today announced the promotion of Shruthi Narayan to President of the company, effective September 1, 2025. She will continue to rep... |
| 29 Jul 2025 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. |
| 30 May 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Dover, County of Kent, State of Delaware. |
| 23 Apr 2025 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. |
| 21 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire f... |
| 18 Feb 2025 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., Feb. 18, 2025 /PR Newswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. |
| 30 Oct 2024 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024. |
| 13 Aug 2024 |
8-K: Other Events
ALAMEDA, Calif., Aug. 13, 2024 /PRNewswire/ – Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today announced that its Board of Directors approved on August 5, 2024 a share repurchase authorization in the amount of ... |
| 30 Jul 2024 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., July 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2024. |
| 07 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
(a)Penumbra, Inc. (“Penumbra” or the “Company”) held its Annual Meeting of Stockholders on June 5, 2024 (the “Annual Meeting”). Proxies for the Annual Meeting were solicited pursuant to Regulation 14A of the Securities Exchange Act of 19... |
| 07 May 2024 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif., May 7, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. |
| 21 Mar 2024 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Penumbra, Inc.'s Form 8-K dated March 17, 2024, and we agree with the statements made in paragraphs 3, 4, 5 and 6 therein. |
Loading...